Insightec developed the Exablate Prime platform, which uses MRI-guided focused ultrasound for incisionless neurosurgery to treat essential tremor and Parkinson's disease. The company received FDA approval for treating advanced Parkinson's disease in 2021. In June 2024, Insightec raised USD 150 million to expand its incisionless neurosurgery treatments and invest in new indications. With over 160 systems installed worldwide, Insightec's technology has been used in nearly 20,000 commercial applications.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.